PMID- 23546966
OWN - NLM
STAT- MEDLINE
DCOM- 20130920
LR  - 20221207
IS  - 1676-5680 (Electronic)
IS  - 1676-5680 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Mar 15
TI  - Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and 
      prognosis in Han Chinese population.
PG  - 820-9
LID - 10.4238/2013.March.15.2 [doi]
AB  - Interleukin-18 (IL-18) has been implicated in a wide variety of cellular 
      functions that affect the biological response to tumors. However, there is 
      insufficient evidence to prove that IL-18 gene variants are associated with risk 
      of prostate cancer. We examined a possible association between two promoter 
      polymorphisms, -137G/C (rs187238) and -607C/A (rs1946518), in the IL-18 gene and 
      prostate cancer occurrence and prognosis in Han Chinese. We used a 
      high-resolution melting method to genotype these two polymorphisms in 375 Chinese 
      Han patients with prostate cancer and in 400 age-matched healthy controls. A 
      hundred and eighty-one prostate cancer patients who had been receiving androgen 
      deprivation therapy, including operational and medical castration, were enrolled 
      to follow-up in this study. Carriers of the GG genotype of the -137G/ C 
      polymorphism had a 2.165-times higher risk of prostate cancer progression than 
      carriers of GC [95% confidence interval (CI) = 1.270-3.687]. Patients with the GG 
      genotype at clinical stages III and IV also had significantly lower rates of 
      progression-free survival (relative risk = 2.174, 95%CI = 1.211-3.906). However, 
      we found no significant association of genotype or allele distributions of these 
      two polymorphisms with occurrence of prostate cancer. We conclude that there is 
      evidence that the IL-18 gene promoter polymorphism -137G/ C influences the 
      prognosis of prostate cancer patients in androgen deprivation therapy, although 
      neither of the two SNPs contributes to prostate cancer development.
FAU - Liu, J M
AU  - Liu JM
AD  - Department of Urology Surgery, West China School of Medicine, West China 
      Hospital, Sichuan University, Sichuan Province, P.R. China.
FAU - Liu, J N
AU  - Liu JN
FAU - Wei, M T
AU  - Wei MT
FAU - He, Y Z
AU  - He YZ
FAU - Zhou, Y
AU  - Zhou Y
FAU - Song, X B
AU  - Song XB
FAU - Ying, B W
AU  - Ying BW
FAU - Huang, J
AU  - Huang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130315
PL  - Brazil
TA  - Genet Mol Res
JT  - Genetics and molecular research : GMR
JID - 101169387
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Asian People/genetics
MH  - China
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Haplotypes
MH  - Humans
MH  - Interleukin-18/*genetics
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Outcome Assessment, Health Care/statistics & numerical data
MH  - *Polymorphism, Single Nucleotide
MH  - Prognosis
MH  - Promoter Regions, Genetic/*genetics
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/ethnology/*genetics/therapy
EDAT- 2013/04/03 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/04/03 06:00
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
AID - gmr1966 [pii]
AID - 10.4238/2013.March.15.2 [doi]
PST - epublish
SO  - Genet Mol Res. 2013 Mar 15;12(1):820-9. doi: 10.4238/2013.March.15.2.